On Par: completion of $410m Anchen acquisition
This article was originally published in Scrip
New Jersey-based Par Pharmaceutical has completed its $410 million acquisition of Anchen Pharmaceuticals, significantly expanding its pipeline and doubling its coverage of the oral extended release market.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.